Abstract | BACKGROUND AND OBJECTIVES: METHODS: All patients with unresectable CRLM treated with HAI and systemic chemotherapy from 2000 to 2009 were included. Survival of patients who were ultimately proven to have low-volume EHD was compared to those without EHD. RESULTS: Three hundred seventy-three patients were included in this study. Seventy-nine percent of patients were previously treated with chemotherapy. One hundred forty-five patients (39%) ultimately proved to have EHD. Median overall survival from HAI pump placement in patients without EHD was 32 months compared to 16 months for patients with EHD, P < 0.001. Median overall survival from HAI pump placement in patients with a single site of EHD was 18 months compared to 9 months for those with multiple sites of EHD, P = 0.01. CONCLUSIONS: In this study of heavily pre-treated patients, overall survival was favorable in patients who proved to have EHD at one site.
|
Authors | John B Ammori, Michael I D'Angelica, Yuman Fong, Andrea Cercek, Ronald P Dematteo, Peter J Allen, T Peter Kingham, Philip B Paty, William R Jarnagin, Nancy E Kemeny |
Journal | Journal of surgical oncology
(J Surg Oncol)
Vol. 106
Issue 8
Pg. 953-8
(Dec 2012)
ISSN: 1096-9098 [Electronic] United States |
PMID | 22753355
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 Wiley Periodicals, Inc. |
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Colorectal Neoplasms
(drug therapy, pathology)
- Follow-Up Studies
- Hepatic Artery
- Humans
- Infusions, Intra-Arterial
- Liver Neoplasms
(drug therapy, physiopathology, secondary)
- Middle Aged
- Prospective Studies
- Survival Analysis
- Treatment Outcome
- Young Adult
|